small molecule

IRON SUCROSE

IRON SUCROSE

Loss of exclusivityFebruary 2026FDA regulatory exclusivity expiry
CompanyMylanSee this company's full patent-cliff portfolio

Drug detail

Brand nameIRON SUCROSE
Active ingredientIRON SUCROSE
StrengthEQ 200MG IRON/10ML (EQ 20MG IRON/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
CGTFebruary 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

IRON SUCROSE patent cliff — loss of exclusivity February 2026 | CliffBio